Influence of nanocrystal size on the in vivo absorption kinetics of caffeine after topical application

The absorption of topically applied substances is challenging due to the effective skin barrier. Encapsulation of substances into nanoparticles was expected to be promising to increase the bioavailability of topically applied products. Since nanoparticles cannot traverse the intact skin barrier, but penetrate into the hair follicles, they could be used to deliver substances via hair follicles, where the active is released and can translocate independently transfollicularly into the viable epidermis. In the present in vivo study, this effect was investigated for caffeine. Caffeine nanocrystals of two sizes, 206 nm and 694 nm, with equal amounts of caffeine were used to study caffeine serum concentration kinetics after topical application on 5 human volunteers. The study demonstrated that at early time points, the smaller nanocrystals were more effective in increasing the bioavailability of caffeine, whereas after 20 min, the serum concentration of caffeine was higher when caffeine was applied by larger nanocrystals. Caffeine was still detectable after 5 days. The area under the curve could be increased by 82% when the 694 nm nanocrystals were applied. Especially larger sized nanocrystals seem to be a promising type of nanoparticulate preparation to increase the bioavailability of topically applied drugs via the transfollicular penetration pathway.

Maximum Loaded Amorphous Azithromycin Produced Using the Wetness Impregnation Method with Fractional Steps for Dermal Prophylaxis Against Lyme Disease

Azithromycin was loaded onto the μm-sized mesoporous silica Davisil^® SP53D-11920 using the wetness impregnation method with fractional steps (WIFS) and further incorporated into a 5 % hydroxypropyl cellulose gel to prevent Lyme disease. Maximum loadings (32.0 % w/w and 33.2 % w/w) were produced by different concentrated loading solutions and determined by X-ray diffraction (XRD). A total of 24 months stability of the amorphous azithromycin state in the silica (33.2 % loading) and 18 months stability in the gel (33.2 % loading) at 4 °C were also confirmed by XRD. The higher kinetic solubility at 40 min (1,300 μg/mL versus 93 μg/mL) and higher porcine ear skin penetration compared to the raw drug powder indicated higher dermal bioavailability of the azithromycin-loaded silica (32.0 % loading), even when compared to the "gold standard" nanocrystals and another clinical effective azithromycin formulation with ethanol. In summary, maximum loaded silicas with azithromycin by WIFS is a promising dermal formulation for prophylaxis against Lyme disease.

Azithromycin nanocrystals for dermal prevention of tick bite infections

Azithromycin was optimized as nanocrystals with a drug content of 10.0 % (w/w) and a surfactant D-^α -tocopheryl polyethylenglycol 1000 succinate (TPGS) content of 1.0 % (w/w) using bead milling for 10 min. The photon correlation spectroscopy (PCS) diameter of the bulk population was 189 nm, laser diffraction (LD) diameter 90 % was 370 nm. Spherical morphology of the optimal nanocrystals was observed by transmission electron microscope (TEM). They were stable over 1 year of storage at 4 °C with the particle size within the nanometer range which was confirmed by PCS, LD and light microscope. An acceptable physical stability of 2 years was also obtained when stored at 4 °C. No microbial attack to the nanocrystals was observed before 3 years storage at 4 °C. The saturation solubility of the nanocrystals was up to triple compared to the raw drug powder (RDP) in water. When incorporated into the gel base, highest penetration efficacy was achieved by the optimal nanocrystals compared to 1) the clinically effective ethanol-solution-gel, 2) the gel with propylene glycol and 3) the gel with RDP in the ex vivo porcine ear penetration study. Even though propylene glycol improved saturation solubility of nanocrystals, it could not bring benefit to nanocrystals in the penetration study. Based on these optimized azithromycin nanocrystals, topical administration for enhanced dermal bioavailability of azithromycin seems to be feasible.

smartLipids® as third solid lipid nanoparticle generation - stabilization of retinol for dermal application

smartLipids® as the 3rd lipid nanoparticle generation are made from a complex lipid mixture. The chaotic particle matrix structure provides higher loading with actives and a firmer inclusion inside the particle matrix being more protective for chemically labile molecules. Thus, these particles were used to develop an optimized retinol formulation. As a new approach, the old concept of the core-shell SLN particles was combined with the novel smartLipids® technology as new stabilization model. Particles were produced by hot high pressure homogenization, loaded with increasing amounts of retinol (5%, 15%, 20%), and both the physical (size, crystallinity) and chemical stability were monitored. According to the core-shell model, the retinol precipitates first, forming a core. Then, in the final solidification stage of the particles the retinol core gets surrounded by a shell of lipid-retinol eutectic mixture. With increasing retinol content, more retinol precipitates in the core and is chemically protected. The model was confirmed by the stability data obtained, e.g. with 5%, 15% and 20% retinol loading, after 60 days of storage 37%, 59% and 75% of retinol remained in the particle suspensions. Thus, chemical stability increased with loading. Size remained unchanged at about 200 nm. Crystallinity showed absence of polymorphic transitions, which can cause expulsion of active from the particle matrix, leading to degradation. After incorporation of the particles into a gel as dermal formulation, similar stability was observed. The developed concept can be transferred to other chemically labile dermal actives, in cosmetics and pharma.

Mucoadhesive dexamethasone acetate-polymyxin B sulfate cationic ocular nanoemulsion--novel combinatorial formulation concept

Dexamethasone acetate (DEX) and polymyxin B sulfate (polymyxin B) were formulated as a cationic nanoemulsion for the treatment of ophthalmic infections. As novel concept, the positive charge to achieve mucoadhesion was not generated by toxicologically and regulatorily problematic cationic lipids or polymers, but by using a positively charged drug in combination with positively charged preservatives. The preservative also acts as co-surfactant to stabilize the emulsion. Nanoemulsions with the lipid phase Eutanol G-Lipoid S 100 (70%:30%) containing 0.05% (w/w) DEX were produced by high pressure homogenization, followed by dissolving the hydrophilic molecules in the water phase, e.g. polymyxin B (0.1%, w/w), cetylpyridinium chloride (0.01%, w/w) and glycerol (2.6%, w/w) to yield a combination product. The particles were below 200 nm with narrow size distribution. The osmolality (374 mOsm/kg), pH (5.31) and viscosity (2.45 mPa s at 37 degrees C) were compatible to the ocular administration. The zeta potential of the optimized formulation was shifted from approx. +9 mV to -11 mV after mucin incubation. The in vitro test revealed no potential cytotoxicity. The final products were stable after 180 days of storage at 4 degrees C and room temperature. The developed product is a viable alternative to the commercial ophthalmic suspensions. Moreover, this concept of generating the positive charge by cationic drug and/or preservative addition can be transferred to other ophthalmic products.

Dermal quercetin smartCrystals®: Formulation development, antioxidant activity and cellular safety

Flavonoids are natural plant pigments, which possess high antioxidative and antiradical activities. However, their poor water solubility led to a limited bioavailability. To overcome this major hurdle, quercetin nanocrystals were produced implementing smartCrystals® technology. This process combines bead milling and subsequent high-pressure homogenization at relatively low pressure (300bar). To test the possibility to develop a dermal formulation from quercetin smartCrystals®, quercetin nanosuspensions were admixed to Lutrol® F127 and hydroxythylcellulose nonionic gels. The physicochemical properties (morphology, size and charge), saturation solubility, dissolution velocity and the antioxidant properties (DPPH assay) as well as the cellular interaction of the produced quercetin smartCrystals® were studied and compared to crude quercetin powder. Quercetin smartCrystals® showed a strong increase in the saturation solubility and the dissolution velocity (7.6 fold). SmartCrystals® loaded or not into gels proved to be physically stable over a period of three months at 25°C. Interestingly, in vitro DPPH assay confirmed the preservation of quercetin antioxidative properties after nanonization. In parallel, the nanocrystalline form did not display cellular toxicity, even at high concentration (50μg/ml), as assayed on an epithelial cell line (VERO cells). In addition, the nanocrystalline form confirmed a protective activity for VERO cells against hydrogen peroxide induced toxicity in vitro. This new formulation presents a promising approach to deliver quercetin efficiently to skin in well-tolerated formulations.

Nanosuspensions of hesperetin: preparation and characterization

Nanosuspensions are a smart formulation principle for dermal applications, as they increase the penetration of poorly soluble substances into the skin. Because microbial stability is a pre-requisite for dermal formulations, water containing formulations need to be preserved. Preservatives are known to possibly impair the physical stability of disperse systems, i.e. by causing agglomeration. These aggregation phenomena might occur during storage of the final product, but can already occur during the production process itself. Therefore, in this study the influence of six different preservatives on the diminution efficiency during the production of hesperetin nanocrystals was investigated. Particles with and without the addition of preservatives were produced by high pressure homogenization (HPH) and the final particle size was analysed and compared to the non-preserved suspension. All preservatives influenced the diminution progress during production and the final particle sizes obtained. The non-preserved suspension yielded a particle size of about 300 nm. Preservation with Hydrolite, Euxyl PE9010, Rokonsal and Phenonip led to sizes of about 400 nm. Preservation with Caprylyl glycol and MultiEx did not lead to nanoparticles (size > 1 microm) and caused a slight agglomeration of the nanosuspensions. Based on zeta potential measurements it was found that the impairment is related to the lipophilicity of the presverative, i.e. the lower the lipophilicity, the less is the impairment. In conclusion, preservatives impair the diminution efficacy during the production of nanosuspensions. Therefore, if possible, preservatives should be added to nanosuspensions after the production process. If preservatives are required during production, highly hydrophilic preservatives, e.g. Hydrolite E, should be used.

Development of lycopene-loaded nanostructured lipid carriers: effect of rice oil and cholesterol

Nanostructured lipid carriers (NLC) were developed using a skin-compatible surfactant and natural lipid materials (rice oil, cholesterol) to incorporate lycopene. Characteristics of the NLC were explored in comparison with nanoemulsions and solid-lipid nanoparticles (SLN). Photon correlation spectroscopy, laser diffractometry (LD) and differential scanning calorimetry were used to determine particle size and thermal stability. Particle size expressed as LD (0.99) was 405 nm for the SLN, 350 nm for the NLC without cholesterol and 287 nm for the NLC with cholesterol. Rice oil and cholesterol enabled the formation of smaller particles, but cholesterol also reduced drug stability in the NLC. To preserve chemical stability of lycopene in the NLC, cholesterol should be avoided and storage should be at 4 degrees C or at room temperature.

Influence of particle shape on plasma protein adsorption and macrophage uptake

The purpose of this study was to evaluate the plasma protein adsorption behavior onto different LIPOMER nanoparticles, especially looking for the first time, if the particle shape affects the protein adsorption pattern. The potential in vivo fate is discussed and compared with previous in vivo animal studies. The two-dimensional polyacrylamide gel electrophoresis (2-D PAGE) was used for identification of adsorbed plasma proteins. Qualitative similar patterns were obtained from the protein adsorption analysis and four apolipoproteins with considerable quantitative differences were identified. Besides the quantitative differences in the adsorbed apolipoproteins, in vitro uptake in the human macrophage cell line U-937 of histocytic lymphoma organ revealed significantly lower uptake of the irregular glycerol monostearate LIPOMER nanoparticles. Therefore, protein adsorption does not seem to play a role in the splenotropic behavior in the sense, that adsorption of opsonins, especially spleen-specific opsonins are required for the uptake. The splenotropic uptake might be favored because all LIPOMER nanoparticles did not adsorb opsonins at all, mediating competitive uptake by liver macrophages. Differences in the in vivo uptake by the spleen were attributed to differences in particle shape with potential super position effect by the quantitative differences in the adsorbed proteins.

Particle size, surface hydrophobicity and interaction with serum of parenteral fat emulsions and model drug carriers as parameters related to RES uptake

Fat emulsions for parenteral nutrition, stabilized by egg lecithin, were characterized in terms of parameters relevant to uptake by the reticuloendothelial system (RES), e.g. size distribution, surface hydrophobicity and adsorption of serum components as a measure of the degree of opsonization. Adsorption of serum components was quantified by zeta potential measurement. Fat emulsions for nutrition were compared with emulsions used for drug delivery and model drug carries for intravenous injection. The emulsions for drug delivery were stabilized by the blockcopolymers Poloxamer 188 and 407 (Pluronic F68 and F127) and Poloxamine 908. Model drug carriers were hydrophobic and hydrophilic polystyrene latex particles. Hydrophilic particles were prepared by adsorption of Poloxamine 908 (coating) onto the particle surface. The hydrophobicity and serum protein adsorption decreased from hydrophobic latex particles to egg lecithin emulsions and blockcopolymer emulsions and particles. The data correlated with that in the literature concerning liver uptake in vivo showing complete RES clearance of hydrophobic latex particles, reduced uptake of egg lecithin emulsions and avoidance of RES uptake by Poloxamine 908 coated particles.

Resveratrol nanosuspensions: interaction of preservatives with nanocrystal production

The effect of six different preservatives on the production process and stability of resveratrol nanosuspensions was investigated. Nanosuspensions of the anti-oxidant resveratrol were prepared by high pressure homogenization (1,500 bar, 20 homogenization cycles). The preservatives used were: caprylyl glycol (0.75%), Euxyl PE 9010 (1.0%), Hydrolite-5 (2.0), Phenonip (0.75%), Rokonsal PB-5 (0.5%) and MultiEx Naturotics (2.0%). Preservation is essential for oral and dermal nanosuspensions, but can impair the stability. The effect of the preservatives on stability as a function of cycle numbers was determined by size measurements (photon correlation spectroscopy (PCS), laser diffraction (LD) and light microscopy). Zeta potential measurements were performed for determination of the Stern potential (measurements in water) and as stability criterion (measurements in original dispersion medium), to elucidate the mechanism of destabilization. The preservatives could be placed into three groups. Hydrolite-5 did not affect the production process and the short term stability, sizes were practically identical to the preservative-free nanosuspension (e.g. PCS diameters 196 nm and 184 nm, respectively). All other preservatives impaired the stability medium to pronounced, being most pronounced for MultiEx Naturotics. Hydrolite-5 is recommended as preservative of choice. A mechanistic model was developed to explain the absence and the different degrees of destabilization. In general, when screening for suitable preservatives, suspensions are produced, different preservatives added and the size changes are monitored over long-term. The destabilizing effect of the preservatives on nanosuspensions became evident when added in the production process immediately, thus this can be used as a screening tool for optimal, non-destabilizing preservatives, replacing or minimizing time-consuming long-term stability studies.

Physical and chemical stability of nanostructured lipid drug carriers (NLC) based on natural lipids from Baikal region (Siberia, Russia)

At the turn of the millennium, a new generation of lipid nanoparticles for pharmacology was developed, nanostructured lipid carriers (NLC). The features of NLC structure which allow the inclusion of natural biologically active lipids in the NLC matrix open a wide prospect for the creation of high performance drug carriers. In this study NLC formulations were developed based on natural lipids from the Siberia region (Russia): fish oil from Lake Baikal fish; polyunsaturated fatty acid fractions and monounsaturated and saturated fatty acid fractions from fish oil and Siberian pine seed oil. Formulation parameters of NLC such as as type of surfactant and storage conditions were evaluated. The data obtained indicated high physical stability of NLC formulated on the basis of pure fish oil stabilized by Tween 80 and NLC formulated on the basis of free fatty acids stabilized by Poloxamer 188. The good chemical stability of the lipid matrix and the high concentrations of the biologically active polyunsaturated fatty acids in the NLC developed open wide prospects for their use in pharmaceutics and cosmetics.

Nanostructured lipid carriers as delivery system for the phopholipase A2 inhibitors PX-18 and PX-13 for dermal application

PX-18 and PX-13 are secretory phospholipase A2-IIA (sPLA2-IIA) inhibitors. An increased expression of sPLA2 in psoriatic skin has been reported. The selective inhibition of this enzyme is a new therapeutic approach. For dermal application PX-18 and PX-13 have been loaded to Nanostructured lipid carriers (NLC). The PX-18-loaded and PX-13-loaded NLC possessed an average particles size of about 250 nm, a narrow particle size distribution (PI < 0.2), a high entrapment efficiency as well as a good physical stability, as already indicated by their high zeta potential. Both NLC formulations have been incorporated into a hydroxyethyl cellulose gel and an o/w cream. In the gel and in the o/w cream PX-18-loaded and PX-13-loaded NLC showed a good physical stability. Neither aggregation nor dissolution of NLC took place.

smartCrystal combination technology--scale up from lab to pilot scale and long term stability

The production of nanocrystals was scaled up from lab scale (20 g) to pilot scale (3 kg), scale up factor 150. The flavonoid apigenin was used as model compound, with potential for pharma, cosmetic and nutraceutical products. Lab scale production was performed by high pressure homogenization (HPH), pilot scale by applying the smartCrystal combination technology (CT), combining pearl milling and a subsequent HPH (1 cycle, 300 bar). The obtained particle sizes were compared on the basis of photon correlation spectroscopy (PCS), laser diffractometry (LD) and light microscopy. The results showed, that assessment of successful scale up depends on the characterization method used, e.g., PCS covering only a part of the particle size range (3 nm-3 microm) of the population, or LD the full size distribution. Long-term stability was predicted on zeta potential (ZP) measurements. Lab and pilot scale possessed sufficiently high ZP values (> 30 mV) for a stable dispersion, but the ZP values were different (5-7 mV). This was explained by differences in the Stern/Nernst potential of the nanocrystals, potentially due to different levels in the crystals where they break in a high energy process (HPH) versus a low energy size reduction (pearl mill). Independent on the production method and batch size, the nanosuspensions proved to be physically stable for 6 months at storage temperatures 4 degrees C, room temperature and 40 degrees C.

Nanostructured lipid carriers as novel carrier for sunscreen formulations

Incorporation of sunscreens into lipid carriers with an increased sun protection factor (SPF) has not yet been fully accomplished. In the present paper, the effectiveness of a sunscreen mixture, incorporated into the novel topical delivery systems, i.e. solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC), used as ultraviolet (UV) protector enhancers with a distinctly higher loading capacity has been developed and evaluated. SLN and NLC were produced by hot high pressure homogenization technique in lab scale production. Size distribution and storage stability of formulations were investigated by laser diffractometry and photon correlation spectroscopy. Nanoparticles were characterized by their melting and recrystallization behaviour recorded by differential scanning calorimetry. Lipid nanoparticles produced with a solid matrix (SLN and NLC) were established as a UV protection system. The loading capacities for molecular sunscreens reported before now were in the range of 10-15%. It was possible to load NLC with up to 70% with molecular sunscreen, which is appropriate to obtain high SPFs with this novel UV protection system. The developed formulations provide a beneficial alternative to conventional sunscreen formulations. The UV protective efficacy of the lipid particles varied with the nature of lipid and UV wavelength.

Preserving hesperetin nanosuspensions for dermal application

Nanosuspensions as aqueous formulations need to be preserved. However, preservatives could vitiate the physical stability of suspensions and to a greater extent nanosuspensions. The impact of six varied preservatives on the physical stability of previously prepared nanosuspensions was studied. The hesperetin nanosuspensions were stabilized using plantacare 2000.30 cycles of high pressure homogenization (HPH) led to a mean photon correlation spectroscopy (PCS) diameter of 335 nm. The preservatives were, caprylyl glycol, Euxyl PE9010, Hydrolite-5, MultiEx naturotics, Phenonip and Rokonsal PB5. On one hand, aggregations were noticed after adding caprylyl glycol, MultiEx naturotics and Phenonip reaching PCS mean diameters of about 500, 1070, 800 nm, respectively. While on the other hand Euxyl PE9010, Hydrolite-5 and Rokonsal PB5 have not significantly affected the physical stability of the nanosuspensions with mean PCS diameters of about 365, 332, 350 nm, respectively. The obtained nanosuspensions were further characterized by measuring zeta potential. From the obtained data it was found that the lipophilicity of the used preservatives demonstrates major influence on the stability of the nanosuspensions, i.e. the higher lipophilicity of the preservative, the stronger the destabilizing effect. Briefly, highly hydrophilic preservatives are recommended to preserve hesperetin nanosuspensions in order to maintain their physical stability during storage.

Nanostructured lipid carriers (NLC) on the basis of Siberian pine (Pinus sibirica) seed oil

Nanostructured lipid carriers (NLC) are new drug systems composed of physiological lipid materials. The possibility of including different types of lipids into the NLC structure revealed the wide prospects for using biologically active natural oils for the development of the cutaneous preparations. In this study the formulation parameters of NLC on the basis of Siberian pine seed oil were evaluated including concentration of lipids, types of surfactants and storage conditions (4 degrees C, 20 degrees C, 40 degrees C). Size distribution and storage stability of formulations produced by hot high pressure homogenisation were investigated by laser diffractometry and photon correlation spectroscopy. The NLC were characterised by their melting behaviour using differential scanning calorimetry. The obtained data indicated the high physical stability of the developed NLC formulations.

Resveratrol nanosuspensions for dermal application--production, characterization, and physical stability

Nanosuspensions of the anti-oxidant resveratrol (5%) were produced for dermal application. Production was performed by high pressure homogenization, applying 1.500 bar up to 30 cycles. Four nanosuspensions were investigated using the stabilizers Tween 80, Poloxamer 188, Plantacare 2000 and Inutec SP1, 1% and 2% respectively. The nanosuspensions were characterized regarding size (photon correlation spectroscopy, laser diffraction), zeta potential and crystallinity. Nanocrystal sizes were about 150 nm (Poloxamer, Plantacare) and about 200 nm (Tween, Inutec); no amorphous fraction could be detected in the nanocrystals. In a short-term stability study (30 days, room temperature), the nanosuspensions with 2% stabilizer proved to be either less stable or at least had no stability advantage over the 1% formulations. All formulations with 1% stabilizer were stable in the short-term study, Plantacare and Inutec showing best stabilization. The stabilization is attributed solely or mainly to steric stabilization, because the measured zeta potentials in the original dispersion media were close to zero (-1 to -5 mV, Tween, Poloxamer, Plantacare) or around -20 mV (Inutec).

Omega-3 fatty acids-loaded lipid nanoparticles for patient-convenient oral bioavailability enhancement

Omega-3 fatty acids are commonly used as food supplements not only for their positive effects on the blood lipid profile but also for their cardioprotective properties. The majority of the commercially available products is made out of fish oil. Apart from the unpleasant side effects, up to 10 capsules per day have to be taken by the patients. This article describes the development and characterisation of an alternative lipid nanoparticle delivery system, which has the potential to reduce side effects and enhance bioavailability.

A novel approach based on lipid nanoparticles (SLN®) for topical delivery of α-lipoic acid

This study describes the development, preparation and characterization of solid lipid nanoparticles (SLN) containing the novel anti-ageing substance alpha-lipoic acid. Lipoic acid is chemically labile, i.e. the degradation products possess an unpleasant odour. Therefore, the active was encapsulated in SLN. A lipid with low melting point (Softisan 601) was selected for preparation of active-loaded SLN after screening the solubility of alpha-lipoic acid in physicochemically different lipids. An entrapment efficiency of 90% (UV analysis) was obtained for all developed formulations using Miranol Ultra C32 as emulsifying agent. Particle size stability was monitored during 3 months storing the samples at 20 degrees C and at 4 degrees C. Results of DSC analysis confirm that these systems are characterized by a solid-like behaviour, although with a very low crystallinity index.

Cyclosporine-loaded solid lipid nanoparticles (SLN®): Drug–lipid physicochemical interactions and characterization of drug incorporation

Solid lipid nanoparticles (SLN) were produced loaded with cyclosporine A in order to develop an improved oral formulation. In this study, the particles were characterized with regard to the structure of the lipid particle matrix, being a determining factor for mode of drug incorporation and drug release. Differential scanning calorimetry (DSC) and wide-angle X-ray scattering (WAXS) measurements were employed for the analysis of the polymorphic modifications and mode of drug incorporation. Particles were produced using Imwitor 900 as lipid matrix (the suspension consisted of 10% particles, 8% Imwitor 900, 2% cyclosporine A), 2.5% Tagat S, 0.5% sodium cholate and 87% water. DSC and WAXS were used to analyse bulk lipid, bulk drug, drug incorporated in the bulk and unloaded and drug-loaded SLN dispersions. The processing of the bulk lipid into nanoparticles was accompanied by a polymorphic transformation from the beta to the alpha-modification. After production, the drug-free SLN dispersions converted back to beta-modification, while the drug-loaded SLN stayed primarily in alpha-modification. After incorporation of cyclosporine A into SLN, the peptide lost its crystalline character. Based on WAXS data, it could be concluded that cyclosporine is molecularly dispersed in between the fatty acid chains of the liquid-crystalline alpha-modification fraction of the loaded SLN.

SolEmuls technology: a way to overcome the drawback of parenteral administration of insoluble drugs

In this article, a nanosuspension of AmB was prepared and mixed with the preformed parenteral emulsion Lipofundin and subjected to high-pressure homogenization (SolEmuls technology). Characterization was performed by photon correlation spectroscopy (PCS), laser diffractometry (LD), and zeta potential measurements. Drug incorporation was studied by using light microscopy. The produced emulsions were further investigated by comparing them with the commercially available Fungizone in regard to antifungal efficiency and toxicity. Results suggest that through the SolEmuls process the AmB forms a reservoir, out of which it is released in such a manner that it is more efficient and less toxic than Fungizone.

Nanostructured lipid carriers (NLC) in cosmetic dermal products

The first generation of lipid nanoparticles was introduced as solid lipid nanoparticles (SLN), the second, improved generation as nanostructured lipid carriers (NLC). Identical to the liposomes, the lipid nanoparticles (NLC) appeared as products first on the cosmetic market. The article gives an overview of the cosmetic benefits of lipid nanoparticles, that means enhancement of chemical stability of actives, film formation, controlled occlusion, skin hydration, enhanced skin bioavailability and physical stability of the lipid nanoparticles as topical formulations. NLC are on the market as concentrates to be used as cosmetic excipients, special formulation challenges for these products are discussed. NLC appeared also in a number of finished cosmetic products world-wide. An overview of these products is provided including their special effects due to the lipid nanoparticles, lipids used for their production and incorporated cosmetic actives.

Rheological and in vitro release behaviour of clotrimazole-containing aqueous SLN dispersions and commercial creams

Clotrimazole is a wide spectrum local imidazolic antifungal agent used in several dermatological creams, having e.g. 1% (m/m) such as Canesten and Fungizid-ratiopharm cream. In the present work, a new system based on solid lipid nanoparticles (SLN) containing the identical concentration of drug has been developed. A comparative study between the rheological properties of the referred creams and the developed aqueous SLN dispersions was carried out. The influence of incorporation of SLN in a standard hydrophilic cream on its flow curves was also assessed. In addition, the release of clotrimazole from the two commercial creams, as well as from aqueous SLN dispersions was studied. Concerning the rheological investigations, all tested commercial creams revealed very low shear rates and no yield points. Lipid nanoparticles having a mean diameter of approx. 200 nm have been incorporated into a hydrophilic cream, in a concentration of 20%, 30% or 40% (m/m). The hydrophilic cream containing 20% of SLN showed a dilatant-like character; however, increasing the percentage of incorporated lipid nanoparticles to 30% and 40% the formulation changed to a more pseudoplastic character, showing yield values of 28 Pa and 39 Pa, respectively. For in vitro release studies, Franz diffusion cells with a cellulose acetate membrane were used to measure the release of clotrimazole from two different commercial formulations in comparison to the aqueous SLN dispersion. After 6 h the amount of drug released was higher than 48% when delivered from both investigated commercial formulations and not higher than 25% when delivered from the aqueous SLN dispersion. The percentage of drug released determined after 24 h was more than 50% for Canesten cream and Fungizid-ratiopharm cream and not higher than 30% for the developed SLN formulation showing its prolonged release character.

Investigation of the factors influencing the incorporation of clotrimazole in SLN and NLC prepared by hot high-pressure homogenization

Clotrimazole, a fungicidal effective for the local treatment of cutaneous and mucosal infections, was incorporated into solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC). The aim was to increase its dermal bioavailability and to control drug release, thereby potentially reducing its side effects. Prior to the release studies, the carrier was optimized and characterized by using different techniques. Laser diffractometry (LD), photon correlation spectroscopy (PCS) and scanning electron microscopy (SEM) indicated that SLN were spherical in shape with a mean size of approximately 400 nm. Some aggregation phenomena occurred during preparation of SEM samples due to the lipid character of the carriers. No physico-chemical instability of the drug-loaded lipid nanoparticles was detected during 2 years of storage at different temperatures. X-ray and DSC results suggested that during storage time the drug remained molecularly dispersed in the lipid matrix. Drug associated to SLN and NLC in its crystal form could be excluded.

Polymorphic behaviour of Compritol888 ATO as bulk lipid and as SLN and NLC

CompritolR888 ATO (glycerol behenate) is widely used as a pharmaceutical excipient in the field of solid dosage forms due to its lubricating properties. It is an amphiphilic material with a high melting point (approximately 70 degrees C) and, therefore, it can also be used to prepare aqueous colloidal dispersions. The aim of this paper is to study the suitability of CompritolR888 ATO for the production of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for the entrapment of a lipophilic model drug. This study assesses the crystalline structure of the bulk lipid, as well as the changes that occur in its crystal lattice with the addition of 'impurities', such as oil (alpha-tocopherol) and drug (ketoconazole), using DSC and X-ray diffraction analysis before and after thermal stress. Aqueous SLN and NLC dispersions were produced using an appropriate surfactant/co-surfactant system and their physicochemical stability was assessed by PCS, LD, DSC and by WAXS. It was found that the crystalline lattice of CompritolR888 ATO is composed of very small amounts of the unstable alpha polymorphic form characteristic of triacylglycerols, which disappears after thermal stress of bulk lipid. Mixing oils and drug molecules which are soluble in this lipid decreased its lattice organization and, thus, was revealed to be suitable for production of lipid nanoparticles containing ketoconazole. However, particle growth could not be avoided during shelf life.

Oral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN®) versus drug nanocrystals

For the development of an optimized oral formulation for cyclosporine A, 2% of this drug has been formulated in solid lipid nanoparticles (SLN, mean size 157 nm) and as nanocrystals (mean size 962 nm). The encapsulation rate of SLN was found to be 96.1%. Nanocrystals are composed of 100% of drug. For the assessment of the pharmacokinetic parameters the developed formulations have been administered via oral route to three young pigs. Comparison studies with a commercial Sandimmun Neoral/Optoral used as reference have been performed. The blood profiles observed after oral administration of the commercial microemulsion Sandimmun revealed a fast absorption of drug leading to the observation of a plasma peak above 1,000 ng/ml within the first 2 h. For drug nanocrystals most of the blood concentrations were in the range between 30 and 70 ng/ml over a period of 14 h. These values were very low, showing huge differences between the measuring time points and between the tested animals. On the contrary, administration of cyclosporine-loaded SLN led to a mean plasma profile with almost similarly low variations in comparison to the reference microemulsion, however with no initial blood peak as observed with the Sandimmun Neoral/Optoral. Comparing the area under the curves (AUC) obtained with the tested animals it could be stated that the SLN formulation avoids side effects by lacking blood concentrations higher than 1,000 ng/ml. In this study it has been proved that using SLN as a drug carrier for oral administration of cyclosporine A a low variation in bioavailability of the drug and simultaneously avoiding the plasma peak typical of the first Sandimmun formulation can be achieved.

Solid lipid nanoparticles (SLN)--effects of lipid composition on in vitro degradation and in vivo toxicity

Solid lipid nanoparticles (SLN) composed of two different lipid matrices were produced to assess their in vivo toxicity in mice. Matrix substances were (i) Compritol (glycerol behenate), a physiological lipid with GRAS status (generally recognized as safe [FDA]), and (ii) cetyl palmitate, a less physiological compound. Physicochemical data proved the suitability of SLN batches for intravenous administration. To assess the in vivo toxicity of produced batches, 400 microl SLN dispersion (lipid content 10% [m/m]) were administered to mice via a bolus injection for six times within a period of 20 days (high dose administration). Additionally, a multiple low dose administration was performed with Compritol-SLN as well (200 microl SLN dispersion, lipid content 2.5% [m/m]). Hepatic and splenic tissues were analysed histologically. In vivo results were dependent on the lipid matrix, as well as on the dose administered. For cetyl palmitate containing SLN no pathological results were obtained, while high dosed Compritol containing formulations led to accumulation of the lipid in liver and spleen and subsequently to pathological alterations. These alterations were found to be partially reversible within six weeks after completing intravenous administration. Liver architecture was nearly recovered. In contrast, low dosed Compritol SLN were well tolerated. Lipid accumulation and pathological alterations of high dosed Compritol SLN were attributed to the slow degradation of the Compritol matrix which could be shown by performing in vitro studies in human plasma.

SLN and NLC for topical delivery of ketoconazole

The clinical use of ketoconazole has been related to some adverse effects in healthy adults, specially local reactions, such as severe irritation, pruritus and stinging. The purpose of the present work is the assessment of ketoconazole stability in aqueous SLN and NLC dispersions, as well as the physicochemical stability of these lipid nanoparticles, which might be useful for targeting this drug into topical route, minimizing the adverse side effects and providing a controlled release. Lipid particles were prepared using Compritol 888 ATO as solid lipid. The natural antioxidant alpha-tocopherol was selected as liquid lipid compound for the preparation of NLC. Ketoconazole loading capacity was identical for both SLN and NLC systems (5% of particle mass). SLN were physically stable as suspensions during 3 months of storage, but the SLN matrix was not able to protect the chemically labile ketoconazole against degradation under light exposure. In contrast, the NLC were able to stabilize the drug, but the aqueous NLC dispersion showed size increase during storage. Potential topical formulations are light-protected packaged SLN or NLC physically stabilized in a gel formulation.

The use of SLN and NLC as topical particulate carriers for imidazole antifungal agents

Two different imidazole antifungal agents have been used as model drugs to be incorporated into solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC), once they are very well established as anti-mycotics for the treatment of topical fungal infections. Because of the high mucoadhesive properties and the strong in situ gelling properties of polyacrylic acid polymers, hydrogels prepared with those macromolecules might be a promising vehicle for imidazole-loaded lipid nanoparticles, such as the above-mentioned SLN and NLC. Thus, in this study Carbopol 934 has been selected for the preparation of semi-solid formulations based on SLN and NLC. Formulations have been stored at three different temperatures before and after particle incorporation into polyacrylate hydrogels. The particle size and the chemical stability of incorporated model drugs have been monitored by HPLC analysis for two years. On the day of production 91.7% and 98.7% of clotrimazole, but only 62.1% and 70.3% of ketoconazole have been recovered from SLN and NLC, respectively. More than 95% of clotrimazole but less than 30% of ketoconazole were detected in the developed formulations after a shelf life of two years. Those values showed to be higher than those obtained with reference emulsions of similar composition and droplet sizes. By rheological measurements a pseudoplastic behaviour with thixotropic properties has been characterized for all semi-solid systems.

Chemical stability of lipid excipients in SLN-production of test formulations, characterisation and short-term stability

The study investigates the chemical stability of lipids used as excipients in the production of solid lipid nanoparticles (SLN). A total of 17 SLN formulations was produced using different lipids. Most of the formulations were produced using identical binary surfactant mixtures and concentrations to study the effect of the chemical nature of the lipid on its stability in SLN. In some formulations surfactants were exchanged to study the contribution of the surfactant. The particles were characterised by photon correlation spectroscopy, laser diffractometry, zeta potential determination and differential scanning calorimetry, the latter to assess potential effects of lipid crystallinity and modifications on lipid stability. Lipid analysis was performed by gas chromatography using a sampling preparation and analysis procedure especially developed for SLN. This short-term study provides primarily information about the stability of the lipid under production conditions, that means high pressure homogenisation (cavitation) at high temperature. No degradation products couldbe detected for all lipids, the production process itself did not impair excipient stability.

Protein rejecting properties of PEG-grafted nanoparticles: influence of PEG-chain length and surface density evaluated by two-dimensional electrophoresis and bicinchoninic acid (BCA)-proteinassay

Poly (ethylene glycol) (PEG)-grafted nanoparticles have been described as potential intravenously injectable, long-circulating drug carriers. The in vivo behaviour of intravenous administered nanoparticles is decisively influenced by the interaction of the particles with the blood proteins. Two-dimensional electrophoresis (2-DE) was employed to study the protein rejecting properties of PEG-grafted polymer nanoparticles, possessing PEG-200 and PEG-400 chains, respectively. The calculated PEG-chain distances varied between 0.39/0.31 nm (PEG-200) and 0.39/0.34 nm (PEG-400), therefore it was possible to study the influence of high chain densities attained by the use of short PEG chains on the protein adsorption. Apart from a stronger protein rejection of small-MW proteins achieved by PEG-chain distance diminution, the affinity of several proteins for the PEG-chains are shown and discussed. Beside the study of protein adsorption patterns, the total protein mass adsorbed to the particles, as well as the extent of protein desorption prior to 2-DE, was investigated using the bicinchoninic acid (BCA)-protein assay.

Solid lipid nanoparticles (SLN) for topical drug delivery: incorporation of the lipophilic drugs N,N-diethyl-m-toluamide and vitamin K

Solid lipid nanoparticles (SLN) for topical delivery were prepared by high pressure homogenization using solid lipids. The lipophilic agents DEET (N,N-diethyl-m-toluamide) and vitamin K were used as model drugs. These topical agents were incorporated into SLN which were characterized. Differential scanning calorimetry studies were performed in order to detect probable interactions in the SLN dispersions. Physical stability of SLN in aqueous dispersions and the effect of drug incorporation into SLN were investigated by photon correlation spectroscopy and zeta potential measurements. Characterization and short-term stability studies showedthat DEET and vitamin K are good candidates for topical SLN formulations.

Skin moisturizing effect and skin penetration of ascorbyl palmitate entrapped in solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) incorporated into hydrogel

This study was performed as a complimentary to our previous study regarding the chemical stability of ascorbyl palmitate (AP) in solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC) and for comparison, in nanoemulsion (NE) incorporated into a hydrogel produced by high pressure homogenization. AP is known as an effective antioxidant that protects tissue integrity similar to vitamin C. Recently, its moisturizing activity in conventional topical formulations was found to be high. The aim of the present study was to investigate the moisturizing potential of AP in SLN and NLC incorporated into hydrogel as colloidal carrier systems. It has been known that SLN and NLC have occlusive effects, but AP incorporation moisturized skin significantly better than placebo in short-term (p < 0.001) and long-term trials (p < 0.01) for both SLN and NLC. In the second part of the study, SLN and NLC were found to sustain the penetration of AP through excised human skin about 1/2 and 2/3 times compared to NE (p < 0.001 and p < 0.01), respectively, due to the solid state of Witepsol E85 in the lipid phase.

Rheology of nanostructured lipid carriers (NLC) suspended in a viscoelastic medium

Colloidal lipid nanoparticle dispersions have been characterized by rheological measurements using two different nanostructured lipid carrier (NLC)-based formulations intended for cosmetic application of substances like sunflower oil and alpha-tocopherol. This study has shown that rheological and viscoelastic properties of aqueous NLC dispersions are quantitatively very different depending on the composition of the oil phase and the temperature of storage despite similar or even identical particle size. NLC were loaded with 30% active ingredient relative to the particle mass. Stearyl alcohol was used as lipid matrix and the particle sizes determined by photon correlation spectroscopy were in the range 210-270 nm. In general, sun flower oil-loaded NLC dispersions showed distinctly higher storage modulus (G'), loss modulus (G") and complex viscosity (eta*). Storage at lower temperature (4 degrees C versus 20 degrees C) delay the build up of a microstructure affected not only by size and stabilizer but also loaded ingredient and storage history after preparation, i.e. storage at room temperature accelerates the build up of a final suspension structure.

Adsorption kinetics of plasma proteins on solid lipid nanoparticles for drug targeting

The interactions of intravenously injected carriers with plasma proteins are the determining factor for the in vivo fate of the particles. In this study the adsorption kinetics on solid lipid nanoparticles (SLN) were investigated and compared to the adsorption kinetics on previously analyzed polymeric model particles and O/W-emulsions. The adsorbed proteins were determined using two-dimensional polyacrylamide gel electrophoresis (2-DE). Employing diluted human plasma, a transient adsorption of fibrinogen was observed on the surface of SLN stabilized with the surfactant Tego Care 450, which in plasma of higher concentrations was displaced by apolipoproteins. This was in agreement with the "Vroman-effect" previously determined on solid surfaces. It says that in the early stages of adsorption, more plentiful proteins with low affinity are displaced by less plentiful with higher affinity to the surface. Over a period of time (0.5 min to 4 h) more interesting for the organ distribution of long circulating carriers, no relevant changes in the composition of the adsorption patterns of SLN, surface-modified with poloxamine 908 and poloxamer 407, respectively, were detected. This is in contrast to the chemically similar surface-modified polymeric particles but well in agreement with the surface-modified O/W-emulsions. As there is no competitive displacement of apolipoproteins on these modified SLN, the stable adsorption patterns may be better exploited for drug targeting than particles with an adsorption pattern being very dependent on contact time with plasma.

Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for application of ascorbyl palmitate

The aim of this study was to improve the chemical stability of ascorbyl palmitate (AP) in a colloidal lipid carrier for its topical use. For this purpose, AP-loaded solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC) and for comparison, a nanoemulsion (NE) were prepared employing the high pressure homogenization technique and stored at room temperature (RT), 4 degrees C and 40 degrees C. During 3 months, physical stability of these formulations compared to placebo formulations which were prepared by the same production method, was studied including recrystallization behaviour of the lipid with differential scanning calorimetry (DSC), particle size distribution and storage stability with photon correlation spectroscopy (PCS) and laser diffractometry (LD). After evaluating data indicating excellent physical stability, AP-loaded SLN, NLC and NE were incorporated into a hydrogel by the same production method as the next step. Degradation of AP by HPLC and physical stability in the same manner were investigated at the same storage temperatures during 3 months. As a result, AP was found most stable in both the NLC and SLN stored at 4 degrees C (p > 0.05) indicating the importance of storage temperature. Nondegraded AP content in NLC, SLN and NE was found to be 71.1% +/- 1.4, 67.6% +/- 2.9 and 55.2% +/- 0.3 after 3 months, respectively. Highest degradation was observed with NE at all the storage temperatures indicating even importance of the carrier structure.

Preparation and characterization of n-dodecyl-ferulate-loaded solid lipid nanoparticles (SLN)

Solid lipid nanoparticles (SLN) containing a novel potential sunscreen n-dodecyl-ferulate (ester of ferulic acid) were developed. The preparation and stability parameters of n-dodecyl-ferulate-loaded SLN have been investigated concerning particle size, surface electrical charge (zeta potential) and matrix crystallinity. The chemical stability of n-dodecyl-ferulate at high temperatures was also assessed by thermal gravimetry analysis. For the selection of the appropriated lipid matrix, chemically different lipids were melted with 4% (m/m) of active and lipid nanoparticles were prepared by the so-called high pressure homogenization technique. n-Dodecyl-ferulate-loaded SLN prepared with cetyl palmitate showed the lowest mean particle size and polydispersity index, as well as the highest physical stability during storage time of 21 days at 4, 20 and 40 degrees C. These colloidal dispersions containing the sunscreen also exhibited the common melting behaviour of aqueous SLN dispersions.

Physicochemical investigations on the structure of drug-free and drug-loaded solid lipid nanoparticles (SLN) by means of DSC and 1H NMR

A solid lipid nanoparticle (SLN) formulation, based on the lipid Imwitor 900, was developed for the incorporation of the poorly water soluble drug RMEZ98. Physicochemical investigations were undertaken to examine the structure and physical stability of the selected lipid as colloidal dispersion in comparison to the bulk material. Using differential scanning calorimetry (DSC) and proton nuclear magnetic resonance (1H NMR) it could be assessed the influence of the incorporated drug on the structure of the lipid matrix. Investigation of mixtures of Imwitor 900 and RMEZ98 showed an increasing effect on the melting/recrystallization behaviour with increasing drug content (5-30%). DSC and 1H NMR results revealed the formation of a crystalline matrix of SLN when prepared by high pressure homogenization excluding, therefore, the phenomenon of supercooled melt. After preparation of RMEZ98-loaded SLN, the drug remained inside the lipid matrix; however, it exhibited only a small effect on the recrystallization behaviour of Imwitor 900 at the lowest payload required for a therapeutic effect (4% m/m with regard to the lipid matrix). Furthermore, the incorporation of RMEZ98 revealed no distinct influence on the particle size distribution. Imwitor 900 proved to be a suitable lipid for the drug RMEZ98, i.e. possessing a sufficient loading capacity and simultaneously physical stability.

Liquid and semisolid SLN dispersions for topical application: rheological characterization

Aqueous dispersions of solid lipid nanoparticles (SLN) are promising drug carrier systems for topical application. A drawback, however, is the need of incorporating the SLN dispersion in commonly used dermal carriers (creams, gels) to obtain the required semisolid consistency for dermal application. This study describes the production of SLN dispersions having the desired semisolid consistency by a one-step process. Physical characterization of these systems in terms of particle size and rheological properties revealed some interesting features. Despite the high lipid content it was possible to produce colloidal dispersions by high pressure homogenization. Continuous flow measurements revealed systems with yield point, plastic flow and thixotropy. Oscillation measurements proved the viscoelastic microstructure of the SLN dispersions. Higher concentrated SLN dispersions were found to have a prevailing elastic component in contrast to lower concentrated systems. Viscoelastic properties of a 40% SLN dispersion were found to be comparable to standard dermal preparations. Storage stability at room temperature in terms of particle size could be demonstrated over a 6-month period. The development of the gel structure of semisolid SLN dispersions is delayed comparable to commercial O/W creams with non-ionic emulsifiers. Parameters like concentration of the dispersed phase, particle size and particle shape were identified as significant factors influencing the microstructure of these complex semisolid systems.

Comparative study between the viscoelastic behaviors of different lipid nanoparticle formulations

Application of drug substances to the skin for systemic absorption or action in a particular layer of the skin is a rather old approach. However, over the last years it has received much more attention, as a consequence of the development of new membrane-moderated and matrix reservoir devices. As new reservoir systems, solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) have been successfully tested for dermal application of different physicochemical substances. The knowledge obtained from rheological investigations of these systems may be highly useful for the characterization of the newly developed topical formulation. In the present study, an oscillation frequency sweep test was used for the evaluation of storage modulus (G'), loss modulus (G''), and complex viscosity (eta*) of twelve different SLN and NLC formulations, over a frequency range from 0 to 10 Hz. The lipidic aqueous dispersions were prepared using three different solid lipids (Softisan138, Compritol888, and stearyl alcohol) as matrix material. Miglyol812, tocopherol, sunflower oil, and long-chain triacylglycerols were the chosen liquid lipids for NLC preparation. The objective of the present work was to investigate the effect of these different liquid lipids on the rheological properties of aqueous dispersions of NLC as model systems. It was found that the liquid oil component of the formulation has a strong influence on the viscoelastic parameters, which are dependent on the particle size, zeta potential, and crystallinity of the lipid particles, as well as on the solid lipid used.

Evaluation of the physical stability of SLN and NLC before and after incorporation into hydrogel formulations

Aqueous dispersions of lipid nanoparticles are being investigated as drug delivery systems for different therapeutic purposes. One of their interesting features is the possibility of topical use, for which these systems have to be incorporated into commonly used dermal carriers, such as creams or hydrogels, in order to have a proper semisolid consistency. For the present investigation four different gel-forming agents (xanthan gum, hydroxyethylcellulose 4000, Carbopol943 and chitosan) were selected for hydrogel preparation. Aqueous dispersions of lipid nanoparticles--solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC)--made from tripalmitin were prepared by hot high pressure homogenization and then incorporated into the freshly prepared hydrogels. NLC differ from SLN due to the presence of a liquid lipid (Miglyol812) in the lipid matrix. Lipid nanoparticles were physically characterized before and after their incorporation into hydrogels. By means of rheological investigations it could be demonstrated that physical properties of the dispersed lipid phase have a great impact on the rheological properties of the prepared semisolid formulations. By employing an oscillation frequency sweep test, significant differences in elastic response of SLN and NLC aqueous dispersions could be observed.

Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery

Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) are colloidal carrier systems providing controlled release profiles for many substances. Clotrimazole-loaded SLN and NLC were prepared by the hot high pressure homogenization technique in order to evaluate the physical stability of these particles, as well as the entrapment efficiency of this lipophilic drug and its in vitro release profile. The particle size was analyzed by PCS and LD showing that the particles remained in their colloidal state during 3 months of storage at 4, 20 and 40 degrees C. For all tested formulations the entrapment efficiency was higher than 50%. The obtained results also demonstrate the use of these lipid nanoparticles as modified release formulations for lipophilic drugs over a period of 10 h.